Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
- Yousef Zakharia
- , Robert R. McWilliams
- , Olivier Rixe
- , Joseph Drabick
- , Montaser F. Shaheen
- , Kenneth F. Grossmann
- , Ravindra Kolhe
- , Rafal Pacholczyk
- , Ramses Sadek
- , Lucinda L. Tennant
- , Christopher M. Smith
- , Eugene P. Kennedy
- , Charles J. Link
- , Nicholas N. Vahanian
- , Jiayi Yu
- , Steven S. Shen
- , Erik L. Brincks
- , Gabriela R. Rossi
- , David Munn
- , Mohammed Milhem
Research output: Contribution to journal › Article › peer-review
92
Link opens in a new tab
Scopus
citations